FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553710623> ?p ?o ?g. }

• W2553710623 endingPage "35300" @default.
• W2553710623 startingPage "35289" @default.
• W2553710623 abstract "// Rodrigo A. Toledo 1,4,* , Antonio Cubillo 1,2,* , Estela Vega 1,2 , Elena Garralda 1,2 , Rafael Alvarez 1,2 , Lisardo U. de la Varga 1,2 , Jesús R. Pascual 1,2 , Gema Sánchez 1,4 , Francesca Sarno 1,4 , Susana H. Prieto 3 , Sofía Perea 1,4 , Pedro P. Lopéz-Casas 4 , Fernando López-Ríos 3 and Manuel Hidalgo 4,5 1 Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain 2 Universidad San Pablo CEU, Madrid, Spain 3 Laboratorio de Dianas Terapeúticas, Madrid, Spain 4 Spanish National Cancer Research Centre (CNIO), Madrid, Spain 5 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA * These authors have contributed equally to this manuscript Correspondence to: Rodrigo A. Toledo, email: // Manuel Hidalgo, email: // Keywords : colorectal cancer, cfDNA, liquid biopsy, anti-EGFR, cetuximab Received : October 13, 2016 Accepted : October 24, 2016 Published : November 11, 2016 Abstract Cancer genomics and translational medicine rely on the molecular profiling of patient’s tumor obtained during surgery or biopsy. Alternatively, blood is a less invasive source of tumor DNA shed, amongst other ways, as cell-free DNA (cfDNA). Highly-sensitive assays capable to detect cancer genetic events from patient’s blood plasma became popularly known as liquid biopsy (LqB). Importantly, retrospective studies including small number of selected patients with metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapy have shown LqB capable to detect the acquired clonal mutations in RAS genes leading to therapy resistance. However, the usefulness of LqB in the real-life clinical monitoring of these patients still lack additional validation on controlled studies. In this context, we designed a prospective LqB clinical trial to monitor newly diagnosed KRAS wild-type (wt) mCRC patients who received a standard FOLFIRI-cetuximab regimen. We used BEAMing technique for evaluate cfDNA mutations in KRAS , NRAS, BRAF, and PIK3CA in twenty-five patients during a 2-y period. A total of 2,178 cfDNA mutation analyses were performed and we observed that: a) continued wt circulating status was correlated with a prolonged response; b) smoldering increases in mutant cfDNA were correlated with acquired resistance; while c) mutation upsurge/explosion anticipated a remarkable clinical deterioration. The current study provides evidences, obtained for the first time in an unbiased and prospective manner, that reinforces the utility of LqB for monitoring mCRC patients." @default.
• W2553710623 created "2016-11-30" @default.
• W2553710623 creator A5000928175 @default.
• W2553710623 creator A5013760636 @default.
• W2553710623 creator A5033798997 @default.
• W2553710623 creator A5038041992 @default.
• W2553710623 creator A5043940766 @default.
• W2553710623 creator A5060432507 @default.
• W2553710623 creator A5063554824 @default.
• W2553710623 creator A5071430061 @default.
• W2553710623 creator A5072151730 @default.
• W2553710623 creator A5075827634 @default.
• W2553710623 creator A5077601839 @default.
• W2553710623 creator A5082250124 @default.
• W2553710623 creator A5086046134 @default.
• W2553710623 creator A5086660695 @default.
• W2553710623 date "2016-11-11" @default.
• W2553710623 modified "2023-10-16" @default.
• W2553710623 title "Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab" @default.
• W2553710623 cites W1493048246 @default.
• W2553710623 cites W1528661249 @default.
• W2553710623 cites W1904761682 @default.
• W2553710623 cites W1914351667 @default.
• W2553710623 cites W1988290769 @default.
• W2553710623 cites W2062109911 @default.
• W2553710623 cites W2066560754 @default.
• W2553710623 cites W2085633477 @default.
• W2553710623 cites W2089135124 @default.
• W2553710623 cites W2095201384 @default.
• W2553710623 cites W2116731538 @default.
• W2553710623 cites W2122108723 @default.
• W2553710623 cites W2155311724 @default.
• W2553710623 cites W2165948908 @default.
• W2553710623 cites W2171237493 @default.
• W2553710623 cites W2172240227 @default.
• W2553710623 cites W2292338160 @default.
• W2553710623 cites W4234746319 @default.
• W2553710623 cites W4235642752 @default.
• W2553710623 cites W4235857807 @default.
• W2553710623 cites W4376848401 @default.
• W2553710623 doi "https://doi.org/10.18632/oncotarget.13311" @default.
• W2553710623 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5471055" @default.
• W2553710623 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27852040" @default.
• W2553710623 hasPublicationYear "2016" @default.
• W2553710623 type Work @default.
• W2553710623 sameAs 2553710623 @default.
• W2553710623 citedByCount "46" @default.
• W2553710623 countsByYear W25537106232017 @default.
• W2553710623 countsByYear W25537106232018 @default.
• W2553710623 countsByYear W25537106232019 @default.
• W2553710623 countsByYear W25537106232020 @default.
• W2553710623 countsByYear W25537106232021 @default.
• W2553710623 countsByYear W25537106232022 @default.
• W2553710623 countsByYear W25537106232023 @default.
• W2553710623 crossrefType "journal-article" @default.
• W2553710623 hasAuthorship W2553710623A5000928175 @default.
• W2553710623 hasAuthorship W2553710623A5013760636 @default.
• W2553710623 hasAuthorship W2553710623A5033798997 @default.
• W2553710623 hasAuthorship W2553710623A5038041992 @default.
• W2553710623 hasAuthorship W2553710623A5043940766 @default.
• W2553710623 hasAuthorship W2553710623A5060432507 @default.
• W2553710623 hasAuthorship W2553710623A5063554824 @default.
• W2553710623 hasAuthorship W2553710623A5071430061 @default.
• W2553710623 hasAuthorship W2553710623A5072151730 @default.
• W2553710623 hasAuthorship W2553710623A5075827634 @default.
• W2553710623 hasAuthorship W2553710623A5077601839 @default.
• W2553710623 hasAuthorship W2553710623A5082250124 @default.
• W2553710623 hasAuthorship W2553710623A5086046134 @default.
• W2553710623 hasAuthorship W2553710623A5086660695 @default.
• W2553710623 hasBestOaLocation W25537106231 @default.
• W2553710623 hasConcept C121608353 @default.
• W2553710623 hasConcept C126322002 @default.
• W2553710623 hasConcept C143998085 @default.
• W2553710623 hasConcept C2775934546 @default.
• W2553710623 hasConcept C2776705615 @default.
• W2553710623 hasConcept C2779529041 @default.
• W2553710623 hasConcept C2779742542 @default.
• W2553710623 hasConcept C2779998722 @default.
• W2553710623 hasConcept C2780259306 @default.
• W2553710623 hasConcept C526805850 @default.
• W2553710623 hasConcept C71924100 @default.
• W2553710623 hasConceptScore W2553710623C121608353 @default.
• W2553710623 hasConceptScore W2553710623C126322002 @default.
• W2553710623 hasConceptScore W2553710623C143998085 @default.
• W2553710623 hasConceptScore W2553710623C2775934546 @default.
• W2553710623 hasConceptScore W2553710623C2776705615 @default.
• W2553710623 hasConceptScore W2553710623C2779529041 @default.
• W2553710623 hasConceptScore W2553710623C2779742542 @default.
• W2553710623 hasConceptScore W2553710623C2779998722 @default.
• W2553710623 hasConceptScore W2553710623C2780259306 @default.
• W2553710623 hasConceptScore W2553710623C526805850 @default.
• W2553710623 hasConceptScore W2553710623C71924100 @default.
• W2553710623 hasIssue "21" @default.
• W2553710623 hasLocation W25537106231 @default.
• W2553710623 hasLocation W25537106232 @default.
• W2553710623 hasLocation W25537106233 @default.
• W2553710623 hasLocation W25537106234 @default.
• W2553710623 hasLocation W25537106235 @default.

• next